News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma brings forward publication date for full year report 2013

February 18, 2014

PledPharma AB
Company Announcement

PledPharma brings forward publication date for full year report 2013

Stockholm, 2014-02-18 15:25 CET (GLOBE NEWSWIRE) -- 

PledPharma AB has decided to bring forward the date of publication for the full
year report 2013 from 21 February to 19 February 2014. 

For further information, please contact:

Jacques Näsström, CEO

+46 737 13 09 79

Michaela Gertz, CFO

+46 709 26 17 75

About PledPharma

PledPharma is a Swedish pharmaceutical company that develops new for prevention
of life threatening diseases related to oxidative stress. The initial objective
is to develop a drug that reduces the serious side effects associated with
chemotherapy. The current market for supportive cancer care is some USD 10
billion. PledPharma also evaluates an existing medicines possibility to reduce
the damage that occurs on the heart muscle when a patient suffers from
myocardial infarction. In addition to these projects, the company is also
evaluating opportunities of using the technology platform in other medical
areas where there is a significant unmet medical need in other diseases.
PledPharma has the potential to offer patients valuable and unique treatments
for serious life-threatening diseases where there is an opportunity for
"breakthrough therapy" designation. It also means that the company has the
potential to offer shareholders a good return on their investment. PledPharma
(STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is
the Certified Adviser. For further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10